{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:47:57Z","timestamp":1787838477306,"version":"build-2784847793"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide. Currently, sorafenib is the standard first-line drug for patients with advanced HCC. However, long-term exposure to sorafenib often results in reduced sensitivity of tumour cells to the drug, leading to acquired resistance. Therefore, developing new compounds to treat sorafenib resistance is urgently needed. Although benzimidazole and its derivatives have been reported to exert antimicrobial and antitumour effects, the anti-drug resistance potential of these molecules is still unknown. In this study, we established sorafenib-resistant (SR) cell lines and an acquired sorafenib resistance xenograft model. We showed that treatment with a benzimidazole derivative bearing a pyrrolidine side chain (compound <jats:bold>9a<\/jats:bold>) inhibited the proliferation of SR cells by blocking the phosphorylation of AKT, p70S6 and the downstream molecule RPS6. In addition, caspase 3\/PARP-dependent apoptotic signals were induced in <jats:bold>9a<\/jats:bold>-treated cells. Regarding epithelial-mesenchymal transition (EMT) activities, <jats:bold>9a<\/jats:bold> treatment significantly suppressed the migration of SR cells. In particular, the levels of EMT-related transcription factors (snail, slug and twist) and mesenchymal markers (vimentin and N-cadherin) were downregulated. In the acquired sorafenib resistance xenograft model, compound <jats:bold>9a<\/jats:bold> administration decreased the growth of tumours with acquired sorafenib resistance and the expression of the HCC markers \u03b1-fetoprotein, glypican 3 and survivin. In conclusion, treatment with this compound may be a novel therapeutic strategy for patients with sorafenib resistance.<\/jats:p>","DOI":"10.1038\/s41598-019-53863-2","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T11:02:41Z","timestamp":1574334161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9218-6532","authenticated-orcid":false,"given":"Fat-Moon","family":"Suk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Lien","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hua","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack P.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jen","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"key":"53863_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 68, 394\u2013424, https:\/\/doi.org\/10.3322\/caac.21492 (2018).","journal-title":"CA: a cancer journal for clinicians"},{"key":"53863_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach, J. K. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67, 358\u2013380, https:\/\/doi.org\/10.1002\/hep.29086 (2018).","journal-title":"Hepatology"},{"key":"53863_CR3","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix, J. & Sherman, M. & American Association for the Study of Liver, D. Management of hepatocellular carcinoma: an update. Hepatology 53, 1020\u20131022, https:\/\/doi.org\/10.1002\/hep.24199 (2011).","journal-title":"Hepatology"},{"key":"53863_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm, S. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature reviews. Drug discovery 5, 835\u2013844, https:\/\/doi.org\/10.1038\/nrd2130 (2006).","journal-title":"Nature reviews. Drug discovery"},{"key":"53863_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00204-012-0931-2","volume":"87","author":"RN Aravalli","year":"2013","unstructured":"Aravalli, R. N., Cressman, E. N. & Steer, C. J. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Archives of toxicology 87, 227\u2013247, https:\/\/doi.org\/10.1007\/s00204-012-0931-2 (2013).","journal-title":"Archives of toxicology"},{"key":"53863_CR6","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/hep.22580","volume":"48","author":"RN Aravalli","year":"2008","unstructured":"Aravalli, R. N., Steer, C. J. & Cressman, E. N. Molecular mechanisms of hepatocellular carcinoma. Hepatology 48, 2047\u20132063, https:\/\/doi.org\/10.1002\/hep.22580 (2008).","journal-title":"Hepatology"},{"key":"53863_CR7","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer research 64, 7099\u20137109, https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1443 (2004).","journal-title":"Cancer research"},{"key":"53863_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The Lancet. Oncology 10, 25\u201334, https:\/\/doi.org\/10.1016\/S1470-2045(08)70285-7 (2009).","journal-title":"The Lancet. Oncology"},{"key":"53863_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. The New England journal of medicine 359, 378\u2013390, https:\/\/doi.org\/10.1056\/NEJMoa0708857 (2008).","journal-title":"The New England journal of medicine"},{"key":"53863_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2015.06.019","volume":"367","author":"J Chen","year":"2015","unstructured":"Chen, J. et al. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer letters 367, 1\u201311, https:\/\/doi.org\/10.1016\/j.canlet.2015.06.019 (2015).","journal-title":"Cancer letters"},{"key":"53863_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/cncr.24029","volume":"115","author":"T Yau","year":"2009","unstructured":"Yau, T. et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 115, 428\u2013436, https:\/\/doi.org\/10.1002\/cncr.24029 (2009).","journal-title":"Cancer"},{"key":"53863_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0169-4758(90)90226-T","volume":"6","author":"LB Townsend","year":"1990","unstructured":"Townsend, L. B. & Wise, D. S. The synthesis and chemistry of certain anthelmintic benzimidazoles. Parasitology today 6, 107\u2013112 (1990).","journal-title":"Parasitology today"},{"key":"53863_CR13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1021\/cr60151a002","volume":"48","author":"JB Wright","year":"1951","unstructured":"Wright, J. B. The chemistry of the benzimidazoles. Chemical reviews 48, 397\u2013541 (1951).","journal-title":"Chemical reviews"},{"key":"53863_CR14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0021-9258(18)72045-0","volume":"152","author":"DW Woolley","year":"1944","unstructured":"Woolley, D. W. Some biological effects produced by benzimidazole and their reversal by purines. J Biol Chem 152, 225\u2013232 (1944).","journal-title":"J Biol Chem"},{"key":"53863_CR15","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.ejmech.2008.06.026","volume":"44","author":"M Tuncbilek","year":"2009","unstructured":"Tuncbilek, M., Kiper, T. & Altanlar, N. Synthesis and in vitro antimicrobial activity of some novel substituted benzimidazole derivatives having potent activity against MRSA. Eur J Med Chem 44, 1024\u20131033, https:\/\/doi.org\/10.1016\/j.ejmech.2008.06.026 (2009).","journal-title":"Eur J Med Chem"},{"key":"53863_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21141-2","volume":"8","author":"C Kong","year":"2018","unstructured":"Kong, C. et al. Suppression of Staphylococcus aureus biofilm formation and virulence by a benzimidazole derivative, UM-C162. Scientific reports 8, 2758, https:\/\/doi.org\/10.1038\/s41598-018-21141-2 (2018).","journal-title":"Scientific reports"},{"key":"53863_CR17","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1016\/j.ejmech.2009.05.021","volume":"44","author":"RV Shingalapur","year":"2009","unstructured":"Shingalapur, R. V., Hosamani, K. M. & Keri, R. S. Synthesis and evaluation of in vitro anti-microbial and anti-tubercular activity of 2-styryl benzimidazoles. Eur J Med Chem 44, 4244\u20134248, https:\/\/doi.org\/10.1016\/j.ejmech.2009.05.021 (2009).","journal-title":"Eur J Med Chem"},{"key":"53863_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ejmech.2013.03.049","volume":"64","author":"HZ Zhang","year":"2013","unstructured":"Zhang, H. Z., Damu, G. L., Cai, G. X. & Zhou, C. H. Design, synthesis and antimicrobial evaluation of novel benzimidazole type of Fluconazole analogues and their synergistic effects with Chloromycin, Norfloxacin and Fluconazole. Eur J Med Chem 64, 329\u2013344, https:\/\/doi.org\/10.1016\/j.ejmech.2013.03.049 (2013).","journal-title":"Eur J Med Chem"},{"key":"53863_CR19","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1016\/j.ejmech.2010.03.050","volume":"45","author":"F Hernandez-Luis","year":"2010","unstructured":"Hernandez-Luis, F. et al. Synthesis and biological activity of 2-(trifluoromethyl)-1H-benzimidazole derivatives against some protozoa and Trichinella spiralis. Eur J Med Chem 45, 3135\u20133141, https:\/\/doi.org\/10.1016\/j.ejmech.2010.03.050 (2010).","journal-title":"Eur J Med Chem"},{"key":"53863_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.actatropica.2017.08.022","volume":"176","author":"G de Andrade Picanco","year":"2017","unstructured":"de Andrade Picanco, G. et al. A benzimidazole derivative (RCB15) in vitro induces the alternative energetic metabolism and glycolysis in Taenia crassiceps cysticerci. Acta tropica 176, 288\u2013292, https:\/\/doi.org\/10.1016\/j.actatropica.2017.08.022 (2017).","journal-title":"Acta tropica"},{"key":"53863_CR21","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/BF02973901","volume":"29","author":"SM Rida","year":"2006","unstructured":"Rida, S. M., El-Hawash, S. A. M., Fahmy, H. T. Y., Hazzaa, A. A. & El-Meligy, M. M. M. Synthesis of novel benzofuran and related benzimidazole derivatives for evaluation of in vitro anti-HIV-1, anticancer and antimicrobial activities. Arch Pharm Res 29, 826\u2013833 (2006).","journal-title":"Arch Pharm Res"},{"key":"53863_CR22","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.1016\/j.bmc.2010.05.076","volume":"18","author":"Y Luo","year":"2010","unstructured":"Luo, Y. et al. Design and synthesis of novel benzimidazole derivatives as inhibitors of hepatitis B virus. Bioorgan Med Chem 18, 5048\u20135055, https:\/\/doi.org\/10.1016\/j.bmc.2010.05.076 (2010).","journal-title":"Bioorgan Med Chem"},{"key":"53863_CR23","doi-asserted-by":"publisher","first-page":"8422","DOI":"10.1128\/JVI.00404-16","volume":"90","author":"T Vausselin","year":"2016","unstructured":"Vausselin, T. et al. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus. Journal of virology 90, 8422\u20138434, https:\/\/doi.org\/10.1128\/JVI.00404-16 (2016).","journal-title":"Journal of virology"},{"key":"53863_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ejmech.2014.11.053","volume":"97","author":"G Yadav","year":"2015","unstructured":"Yadav, G. & Ganguly, S. Structure activity relationship (SAR) study of benzimidazole scaffold for different biological activities: A mini-review. Eur J Med Chem 97, 419\u2013443, https:\/\/doi.org\/10.1016\/j.ejmech.2014.11.053 (2015).","journal-title":"Eur J Med Chem"},{"key":"53863_CR25","doi-asserted-by":"publisher","first-page":"e1686","DOI":"10.1038\/cddis.2015.25","volume":"6","author":"B Chu","year":"2015","unstructured":"Chu, B. et al. A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells. Cell death & disease 6, e1686, https:\/\/doi.org\/10.1038\/cddis.2015.25 (2015).","journal-title":"Cell death & disease"},{"key":"53863_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13046-016-0332-0","volume":"35","author":"M Hasanpourghadi","year":"2016","unstructured":"Hasanpourghadi, M. et al. Targeting of tubulin polymerization and induction of mitotic blockage by Methyl 2-(5-fluoro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylate (MBIC) in human cervical cancer HeLa cell. Journal of experimental & clinical cancer research: CR 35, 58, https:\/\/doi.org\/10.1186\/s13046-016-0332-0 (2016).","journal-title":"Journal of experimental & clinical cancer research: CR"},{"key":"53863_CR27","doi-asserted-by":"publisher","unstructured":"Dai, X. et al. A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma. Oncotarget, https:\/\/doi.org\/10.18632\/oncotarget.14606 (2017).","DOI":"10.18632\/oncotarget.14606"},{"key":"53863_CR28","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jhep.2010.12.043","volume":"55","author":"X Chen","year":"2011","unstructured":"Chen, X. et al. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. Journal of hepatology 55, 838\u2013845, https:\/\/doi.org\/10.1016\/j.jhep.2010.12.043 (2011).","journal-title":"Journal of hepatology"},{"key":"53863_CR29","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1007\/s13277-015-4458-z","volume":"37","author":"JL Ma","year":"2016","unstructured":"Ma, J. L., Zeng, S., Zhang, Y., Deng, G. L. & Shen, H. Epithelial-mesenchymal transition plays a critical role in drug resistance of hepatocellular carcinoma cells to oxaliplatin. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 37, 6177\u20136184, https:\/\/doi.org\/10.1007\/s13277-015-4458-z (2016).","journal-title":"Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine"},{"key":"53863_CR30","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2012.10.021","volume":"329","author":"H van Malenstein","year":"2013","unstructured":"van Malenstein, H. et al. Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer letters 329, 74\u201383, https:\/\/doi.org\/10.1016\/j.canlet.2012.10.021 (2013).","journal-title":"Cancer letters"},{"key":"53863_CR31","doi-asserted-by":"publisher","first-page":"e0185088","DOI":"10.1371\/journal.pone.0185088","volume":"12","author":"J Dong","year":"2017","unstructured":"Dong, J. et al. Activation of phosphatidylinositol 3-kinase\/AKT\/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells. PloS one 12, e0185088, https:\/\/doi.org\/10.1371\/journal.pone.0185088 (2017).","journal-title":"PloS one"},{"key":"53863_CR32","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/aps.2017.5","volume":"38","author":"YJ Zhu","year":"2017","unstructured":"Zhu, Y. J., Zheng, B., Wang, H. Y. & Chen, L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta pharmacologica Sinica 38, 614\u2013622, https:\/\/doi.org\/10.1038\/aps.2017.5 (2017).","journal-title":"Acta pharmacologica Sinica"},{"key":"53863_CR33","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245\u20131255, https:\/\/doi.org\/10.1016\/S0140-6736(11)61347-0 (2012).","journal-title":"Lancet"},{"key":"53863_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics, 2017. CA: a cancer journal for clinicians 67, 7\u201330, https:\/\/doi.org\/10.3322\/caac.21387 (2017).","journal-title":"CA: a cancer journal for clinicians"},{"key":"53863_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4254\/wjh.v5.i7.345","volume":"5","author":"B Zhai","year":"2013","unstructured":"Zhai, B. & Sun, X. Y. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World journal of hepatology 5, 345\u2013352, https:\/\/doi.org\/10.4254\/wjh.v5.i7.345 (2013).","journal-title":"World journal of hepatology"},{"key":"53863_CR36","doi-asserted-by":"publisher","first-page":"7645","DOI":"10.3748\/wjg.v22.i34.7645","volume":"22","author":"S Colagrande","year":"2016","unstructured":"Colagrande, S. et al. Challenges of advanced hepatocellular carcinoma. World journal of gastroenterology 22, 7645\u20137659, https:\/\/doi.org\/10.3748\/wjg.v22.i34.7645 (2016).","journal-title":"World journal of gastroenterology"},{"key":"53863_CR37","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1111\/hepr.12459","volume":"45","author":"M Chuma","year":"2015","unstructured":"Chuma, M., Terashita, K. & Sakamoto, N. New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions. Hepatology research: the official journal of the Japan Society of Hepatology 45, E1\u2013E11, https:\/\/doi.org\/10.1111\/hepr.12459 (2015).","journal-title":"Hepatology research: the official journal of the Japan Society of Hepatology"},{"key":"53863_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.21037\/jgo.2017.02.01","volume":"8","author":"JR Desai","year":"2017","unstructured":"Desai, J. R., Ochoa, S., Prins, P. A. & He, A. R. Systemic therapy for advanced hepatocellular carcinoma: an update. Journal of gastrointestinal oncology 8, 243\u2013255, https:\/\/doi.org\/10.21037\/jgo.2017.02.01 (2017).","journal-title":"Journal of gastrointestinal oncology"},{"key":"53863_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/JHC.S112537","volume":"3","author":"J Trojan","year":"2016","unstructured":"Trojan, J. & Waidmann, O. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. Journal of hepatocellular carcinoma 3, 31\u201336, https:\/\/doi.org\/10.2147\/JHC.S112537 (2016).","journal-title":"Journal of hepatocellular carcinoma"},{"key":"53863_CR40","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3748\/wjg.v25.i7.789","volume":"25","author":"M Kudo","year":"2019","unstructured":"Kudo, M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World journal of gastroenterology 25, 789\u2013807, https:\/\/doi.org\/10.3748\/wjg.v25.i7.789 (2019).","journal-title":"World journal of gastroenterology"},{"issue":"11","key":"53863_CR41","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/cancers10110412","volume":"10","author":"Masatoshi Kudo","year":"2018","unstructured":"Kudo, M. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers 10, https:\/\/doi.org\/10.3390\/cancers10110412 (2018).","journal-title":"Cancers"},{"key":"53863_CR42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56\u201366, https:\/\/doi.org\/10.1016\/S0140-6736(16)32453-9 (2017).","journal-title":"Lancet"},{"key":"53863_CR43","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1002\/cncr.30863","volume":"123","author":"ND Parikh","year":"2017","unstructured":"Parikh, N. D., Singal, A. G. & Hutton, D. W. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. Cancer 123, 3725\u20133731, https:\/\/doi.org\/10.1002\/cncr.30863 (2017).","journal-title":"Cancer"},{"key":"53863_CR44","doi-asserted-by":"publisher","first-page":"16253","DOI":"10.1039\/c6ra28281d","volume":"7","author":"MH Hsu","year":"2017","unstructured":"Hsu, M. H. et al. Treatment with low-dose sorafenib in combination with a novel benzimidazole derivative bearing a pyrolidine side chain provides synergistic anti-proliferative effects against human liver cancer. Rsc Adv 7, 16253\u201316263, https:\/\/doi.org\/10.1039\/c6ra28281d (2017).","journal-title":"Rsc Adv"},{"key":"53863_CR45","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.bbcan.2017.10.002","volume":"1868","author":"L Niu","year":"2017","unstructured":"Niu, L. et al. New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies. Biochimica et biophysica acta. Reviews on cancer 1868, 564\u2013570, https:\/\/doi.org\/10.1016\/j.bbcan.2017.10.002 (2017).","journal-title":"Reviews on cancer"},{"key":"53863_CR46","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/gutjnl-2015-309501","volume":"66","author":"V Tovar","year":"2017","unstructured":"Tovar, V. et al. Tumour initiating cells and IGF\/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut 66, 530\u2013540, https:\/\/doi.org\/10.1136\/gutjnl-2015-309501 (2017).","journal-title":"Gut"},{"key":"53863_CR47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature reviews. Cancer 2, 489\u2013501, https:\/\/doi.org\/10.1038\/nrc839 (2002).","journal-title":"Nature reviews. Cancer"},{"key":"53863_CR48","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1124\/jpet.110.175786","volume":"337","author":"KF Chen","year":"2011","unstructured":"Chen, K. F. et al. Activation of phosphatidylinositol 3-kinase\/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. The Journal of pharmacology and experimental therapeutics 337, 155\u2013161, https:\/\/doi.org\/10.1124\/jpet.110.175786 (2011).","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"key":"53863_CR49","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/1878-0261.12039","volume":"11","author":"P Han","year":"2017","unstructured":"Han, P. et al. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells. Molecular oncology 11, 320\u2013334, https:\/\/doi.org\/10.1002\/1878-0261.12039 (2017).","journal-title":"Molecular oncology"},{"key":"53863_CR50","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejmech.2012.07.023","volume":"55","author":"KF Chen","year":"2012","unstructured":"Chen, K. F. et al. Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity. Eur J Med Chem 55, 220\u2013227, https:\/\/doi.org\/10.1016\/j.ejmech.2012.07.023 (2012).","journal-title":"Eur J Med Chem"},{"key":"53863_CR51","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.neo.2014.06.005","volume":"16","author":"JC Su","year":"2014","unstructured":"Su, J. C. et al. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1\/SHP-1 activation in hepatocellular carcinoma. Neoplasia 16, 595\u2013605, https:\/\/doi.org\/10.1016\/j.neo.2014.06.005 (2014).","journal-title":"Neoplasia"},{"key":"53863_CR52","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1158\/1535-7163.MCT-11-0412","volume":"11","author":"WT Tai","year":"2012","unstructured":"Tai, W. T. et al. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Molecular cancer therapeutics 11, 452\u2013463, https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0412 (2012).","journal-title":"Molecular cancer therapeutics"},{"key":"53863_CR53","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1172\/JCI42615","volume":"120","author":"J Jou","year":"2010","unstructured":"Jou, J. & Diehl, A. M. Epithelial-mesenchymal transitions and hepatocarcinogenesis. The Journal of clinical investigation 120, 1031\u20131034, https:\/\/doi.org\/10.1172\/JCI42615 (2010).","journal-title":"The Journal of clinical investigation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53863-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53863-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53863-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:15:55Z","timestamp":1671293755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53863-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["53863"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-53863-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"19 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17259"}}